Role of kallistatin in pediatric patients with pulmonary arterial hypertension
Background and Objectives. Kallistatin, a serine proteinase inhibitor, exerts its effect by vascular repair, angiogenesis inhibition, strong vasodilation, inhibition of vascular endothelial growth factor (VEGF), antiinflammation, and anti-apoptosis. We hypothesized as to whether it has a prot...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2020-06-01
|
| Series: | The Turkish Journal of Pediatrics |
| Subjects: | |
| Online Access: | https://turkjpediatr.org/article/view/460 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705815082008576 |
|---|---|
| author | Özge Pamukçu Derya Ay Kazım Üzüm Didem Barlakketi Mehmet Köse Ali Baykan Süleyman Sunkak Nazmi Narin |
| author_facet | Özge Pamukçu Derya Ay Kazım Üzüm Didem Barlakketi Mehmet Köse Ali Baykan Süleyman Sunkak Nazmi Narin |
| author_sort | Özge Pamukçu |
| collection | DOAJ |
| description |
Background and Objectives. Kallistatin, a serine proteinase inhibitor, exerts its effect by vascular repair, angiogenesis inhibition, strong vasodilation, inhibition of vascular endothelial growth factor (VEGF), antiinflammation, and anti-apoptosis. We hypothesized as to whether it has a protective role in pulmonary arterial hypertension (PAH).
Methods. The study included 5 subgroups (78 patients; 44 male): Eisenmenger syndrome (n=16), PAH with left to right shunt (n=20), idiopathic PAH (n=7), patients with left to right shunt without PAH (n=19), and patients with innocent heart murmur (n=16). Physical examination, chest radiography, electrocardiography, and transthoracic echocardiography (TTE) were performed for each patient. PAH diagnosis was confirmed by catheterization. Serum kallistatin, tumor necrosis factor alpha (TNF-α), Interleukin-10 (IL-10) and N-terminal pro b-type natriuretic peptide (NT-proBNP) levels were studied for each patient.
Results. The lowest median kallistatin value was found in Eisenmenger syndrome: 1.19 (0.87-3.30) μg/ml. The highest value belonged to control group with innocent murmur: 2.89 (1.19-5.66) μg/ml. Serum levels of kallistatin were significantly lower in patients with PAH (p < 0.05). TNF-α values were increased and IL-10 values were decreased in pulmonary hypertension. However; no correlation was found between kallistatin levels and cytokines.
Conclusions. Kallistatin may have a protective effect in pulmonary arterial hypertension by repairing vascular damage, inhibition of angiogenesis, strong vasodilator effect, inhibiting VEGF, and anti-inflammatory mechanism of action. To our knowledge, our study is the first one that shows the role of kallistatin in pulmonary hypertension. Kallistatin may represent a promising novel therapeutic approach for pulmonary hypertension in the near future.
|
| format | Article |
| id | doaj-art-3db28c2daeca4b1dbd25ce0e1ef6d470 |
| institution | DOAJ |
| issn | 0041-4301 2791-6421 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Hacettepe University Institute of Child Health |
| record_format | Article |
| series | The Turkish Journal of Pediatrics |
| spelling | doaj-art-3db28c2daeca4b1dbd25ce0e1ef6d4702025-08-20T03:16:22ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64212020-06-0162310.24953/turkjped.2020.03.007Role of kallistatin in pediatric patients with pulmonary arterial hypertensionÖzge Pamukçu0Derya Ay1Kazım Üzüm2Didem Barlakketi3Mehmet Köse4Ali Baykan5Süleyman Sunkak6Nazmi Narin7Divisions of Pediatric Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.Divisions of Pediatric Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.Divisions of Pediatric Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.Department of Pediatrics, Department of Biochemistry, Erciyes University Faculty of Medicine, Kayseri, Turkey.Divisions of Pediatric Pulmonology, Erciyes University Faculty of Medicine, Kayseri, Turkey.Divisions of Pediatric Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.Divisions of Pediatric Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.Divisions of Pediatric Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey. Background and Objectives. Kallistatin, a serine proteinase inhibitor, exerts its effect by vascular repair, angiogenesis inhibition, strong vasodilation, inhibition of vascular endothelial growth factor (VEGF), antiinflammation, and anti-apoptosis. We hypothesized as to whether it has a protective role in pulmonary arterial hypertension (PAH). Methods. The study included 5 subgroups (78 patients; 44 male): Eisenmenger syndrome (n=16), PAH with left to right shunt (n=20), idiopathic PAH (n=7), patients with left to right shunt without PAH (n=19), and patients with innocent heart murmur (n=16). Physical examination, chest radiography, electrocardiography, and transthoracic echocardiography (TTE) were performed for each patient. PAH diagnosis was confirmed by catheterization. Serum kallistatin, tumor necrosis factor alpha (TNF-α), Interleukin-10 (IL-10) and N-terminal pro b-type natriuretic peptide (NT-proBNP) levels were studied for each patient. Results. The lowest median kallistatin value was found in Eisenmenger syndrome: 1.19 (0.87-3.30) μg/ml. The highest value belonged to control group with innocent murmur: 2.89 (1.19-5.66) μg/ml. Serum levels of kallistatin were significantly lower in patients with PAH (p < 0.05). TNF-α values were increased and IL-10 values were decreased in pulmonary hypertension. However; no correlation was found between kallistatin levels and cytokines. Conclusions. Kallistatin may have a protective effect in pulmonary arterial hypertension by repairing vascular damage, inhibition of angiogenesis, strong vasodilator effect, inhibiting VEGF, and anti-inflammatory mechanism of action. To our knowledge, our study is the first one that shows the role of kallistatin in pulmonary hypertension. Kallistatin may represent a promising novel therapeutic approach for pulmonary hypertension in the near future. https://turkjpediatr.org/article/view/460IL-10TNFαkallistatinpulmonary hypertension |
| spellingShingle | Özge Pamukçu Derya Ay Kazım Üzüm Didem Barlakketi Mehmet Köse Ali Baykan Süleyman Sunkak Nazmi Narin Role of kallistatin in pediatric patients with pulmonary arterial hypertension The Turkish Journal of Pediatrics IL-10 TNFα kallistatin pulmonary hypertension |
| title | Role of kallistatin in pediatric patients with pulmonary arterial hypertension |
| title_full | Role of kallistatin in pediatric patients with pulmonary arterial hypertension |
| title_fullStr | Role of kallistatin in pediatric patients with pulmonary arterial hypertension |
| title_full_unstemmed | Role of kallistatin in pediatric patients with pulmonary arterial hypertension |
| title_short | Role of kallistatin in pediatric patients with pulmonary arterial hypertension |
| title_sort | role of kallistatin in pediatric patients with pulmonary arterial hypertension |
| topic | IL-10 TNFα kallistatin pulmonary hypertension |
| url | https://turkjpediatr.org/article/view/460 |
| work_keys_str_mv | AT ozgepamukcu roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT deryaay roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT kazımuzum roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT didembarlakketi roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT mehmetkose roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT alibaykan roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT suleymansunkak roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension AT nazminarin roleofkallistatininpediatricpatientswithpulmonaryarterialhypertension |